XOMA (XOMA) Earning Somewhat Positive Press Coverage, Report Shows

Media stories about XOMA (NASDAQ:XOMA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.5280837175341 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Several equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of XOMA in a research report on Thursday, January 18th. ValuEngine upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Wedbush restated a “buy” rating and issued a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. Zacks Investment Research cut shares of XOMA from a “hold” rating to a “sell” rating in a research report on Friday, March 9th. Finally, TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $38.33.

XOMA (XOMA) traded up $0.43 during mid-day trading on Wednesday, reaching $23.63. 173,143 shares of the company’s stock were exchanged, compared to its average volume of 194,197. The company has a debt-to-equity ratio of 2.52, a current ratio of 5.96 and a quick ratio of 5.96. XOMA has a fifty-two week low of $5.27 and a fifty-two week high of $37.25. The company has a market capitalization of $193.24, a PE ratio of 32.40 and a beta of 3.03.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.19. XOMA had a net margin of 27.49% and a negative return on equity of 130.44%. The business had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $4.12 million. equities research analysts forecast that XOMA will post -0.62 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/14/xoma-xoma-earning-somewhat-positive-press-coverage-report-shows.html.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Insider Buying and Selling by Quarter for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply